<DOC>
	<DOCNO>NCT01111422</DOCNO>
	<brief_summary>Peritoneal fibrosis one major cause technical failure patient peritoneal dialysis ( PD ) long period time . Although exact mechanism peritoneal damage PD still remain unclear , generation reactive oxygen specie may responsible progressive membrane dysfunction . N-acetylcysteine ( NAC ) powerful antioxidant show protect peritoneal fibrosis peritoneal dialysis animal model . In study researcher investigate hypothesis NAC protect peritoneal membrane damage .</brief_summary>
	<brief_title>Anti-Oxidant Effect Peritoneal Membrane Peritoneal Dialysis ( PD ) Patients</brief_title>
	<detailed_description>N-Acetylcysteine ( NAC ) know relatively safe beneficial peritoneal dialysis patient dose 1200 mg per day . Patients randomly assign NAC control group prescribe accord protocol . At 2 6 month , Peritoneal equilibrium test ( PET ) perform blood sampling .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Maintenance peritoneal dialysis least 3 month Patients able willing understand , sign date inform consent document , authorize access protect health information Episode peritonitis least 3 month Episodes admission due disease lease 3 month Liver disease Allergic history Nacetylcysteine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Antioxidant</keyword>
	<keyword>Epithelial Mesenchymal Transition</keyword>
	<keyword>peritoneal fibrosis</keyword>
	<keyword>Peritoneal Dialysis , Continuous Ambulatory</keyword>
</DOC>